SAN DIEGO, Sept. 12 -- Gensia, Inc. (Nasdaq: GNSA) today announced that its wholly-owned subsidiary Gensia Laboratories, Ltd., has received approval of an Abbreviated New Drug Application (ANDA) from the Food and Drug Administration (FDA) for fluphenazine decanoate injection USP. Fluphenazine is an injectable drug used in the management of schizophrenia. According to Patrick D. Walsh, President and Chief Operating Officer of Gensia Laboratories, "We received regulatory approval for fluphenazine in approximately nine months. Gensia Laboratories continues to establish a solid record of achievement in multisource injectable drug development." With this ANDA approval, Gensia Laboratories has 24 multisource injectable drugs in its product line and has several additional ANDAs filed with the FDA. Gensia Laboratories also has over 40 additional products in development, as well as a growing contract manufacturing business. Gensia Laboratories, Ltd. is a specialty pharmaceutical company located in Irvine, California with product emphasis in oncology, anesthesiology and key specialty pharmaceuticals. Gensia Laboratories seeks to bring innovation to its multisource products and focuses on products which are difficult to produce. The company also provides contract manufacturing support and services to other pharmaceutical and biotech companies. Gensia, Inc. is a research-based company focused on the discovery, development and commercialization of health care products for the acute care market. For more information, visit Gensia's web site on the Internet at This press release contains forward looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward looking statements, including whether the products in development at Gensia Laboratories will be successfully developed or commercialized, and the risk factors set forth in Gensia's filing on Form 10-K with the Securities and Exchange Commission. These forward looking statements represent the Company's judgment as of the date of this press release. The Company disclaims any intent or obligation to update these forward looking statements.

SOURCE Gensia, Inc. -0- 09/12/96 /CONTACT: Martha L. Hough or Claudia B. Silvas, both of Gensia, 619-546-8300/ (GNSA)

[ Home] [News]